Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,562 across all filing types
Latest filing 2022-06-23 Environmental & Social …
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
110年企業ESG資訊揭露
Environmental & Social Information Classification · 95% confidence The document contains detailed data on environmental, social, and governance (ESG) metrics such as greenhouse gas emissions, energy use, water use, waste management, employee welfare, gender diversity in management, and board composition. These topics align with ESG reporting rather than financial results or corporate governance changes. The document length is short (1799 characters) and it is a structured report of ESG performance indicators, not an announcement or a brief summary. Therefore, it fits the category of Environmental & Social Information (SR).
2022-06-23 Chinese
代重要子公司正峰化學製藥(股)公司公告唯一法人股東 重新指派董事及監察人暨選任董事長
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding changes in the board of directors and supervisory personnel of a subsidiary company. It details the reassignment of directors and supervisors, including names, positions, and effective dates. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements about changes in company board or senior management.
2022-06-21 Chinese
公告本公司董事會通過委任第五屆薪資報酬委員會委員
Board/Management Information Classification · 95% confidence The document is a short announcement (868 characters) about the appointment and reappointment of members to the company's Compensation Committee, including names, dates, and reasons for changes. It does not contain financial data, financial results, or detailed reports. It is an announcement related to changes in board committee members, which falls under Board/Management Information (MANG). The document is not a full report, nor is it a regulatory filing or a report publication announcement. Therefore, the correct classification is MANG with high confidence.
2022-06-21 Chinese
公告本公司董事會通過總經理續任事宜
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the renewal of the general manager's term by the company's board of directors. It includes details such as the date of the board resolution, names and resumes of the outgoing and incoming general manager (which are the same person), and the reason for the change (term expiration and reappointment). There is no financial data, no mention of financial results, no report attached or referenced, and no regulatory certification. The content clearly relates to a management change announcement. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification with high confidence.
2022-06-21 Chinese
111年年報及股東會資料 — 2022_1760_20220608F05.pdf
Regulatory Filings
2022-06-15 Chinese
111年年報及股東會資料 — 2022_1760_20220608F14.pdf
Governance Information Classification · 95% confidence The document is a detailed procedural manual titled '寶齡富錦生技股份有限公司 取得或處分資產處理程序' which translates to 'Asset Acquisition or Disposal Procedures of the Company'. It outlines internal rules and processes for asset acquisition and disposal, including definitions, evaluation procedures, approval processes, disclosure requirements, risk management for derivative transactions, and procedures related to mergers, acquisitions, and share transfers. It references compliance with regulatory standards such as the '公開發行公司取得或處分資產處理準則' (Regulations for Public Companies on Asset Acquisition or Disposal). The document is not a financial report, earnings release, or announcement but a governance and compliance manual detailing internal control and governance practices related to asset transactions and corporate actions. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is a full procedural document, not a brief announcement or certification.
2022-06-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.